Sugi Predict

Sugi Predict / Compounds / Glutamic Acid

Glutamic Acid

Glutamic Acid

SCHEMBL7900440

Cc1ccc(S(=O)(=O)c2ccc(C)cc2)cc1.N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC1A3 P43003 2/20 0.55
▸ SLC1A2 P43004 2/20 0.55
▸ SLC1A1 P43005 2/20 0.55
▸ GRM4 Q14833 2/20 0.55
▸ GRM8 O00222 1/20 0.55
▸ GRM6 O15303 1/20 0.55
▸ GRIN2D O15399 1/20 0.55
▸ GRIN3B O60391 1/20 0.55
▸ GSR P00390 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ GRIK1 P39086 1/20 0.55
▸ GRM5 P41594 1/20 0.55
▸ GRIA1 P42261 1/20 0.55
▸ GRIA2 P42262 1/20 0.55
▸ GRIA3 P42263 1/20 0.55
▸ GRIA4 P48058 1/20 0.55
▸ GRIN1 Q05586 1/20 0.55
▸ GRIN2A Q12879 1/20 0.55
▸ GRIK2 Q13002 1/20 0.55
▸ GRIK3 Q13003 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamic Acid SCHEMBL5196110 0.90 SLC1A3 (0.53) SLC1A3SLC1A2SLC1A1GRM4GRM8
Glutamic Acid SCHEMBL1873097 0.90 SLC1A3 (0.53) SLC1A3SLC1A2SLC1A1GRM4GRM8
D-Glutamate SCHEMBL5196106 0.90 SLC1A3 (0.53) SLC1A3SLC1A2SLC1A1GRM4GRM8
Glutamic Acid SCHEMBL1674904 0.82 GRM8 (0.64) SLC1A3SLC1A2SLC1A1GRM4GRM8
D-Glutamate SCHEMBL7902663 0.82 KIF11 (0.45) SLC1A3SLC1A2SLC1A1GRM4GRM8
Glutamic Acid SCHEMBL4697460 0.82 KIF11 (0.45) SLC1A3SLC1A2SLC1A1GRM4GRM8
D-Glutamate SCHEMBL4692007 0.82 KIF11 (0.45) SLC1A3SLC1A2SLC1A1GRM4GRM8
SCHEMBL11656520 0.80 SLC7A5 (0.56) SLC1A3SLC1A2SLC1A1CYP1A2GAA
Glutamine SCHEMBL29028870 0.79 ALOX15 (0.54) SLC1A3SLC1A2SLC1A1GRM4CYP1A2
SCHEMBL21805464 0.78 ALDH1A1 (0.45) SLC1A3SLC1A2SLC1A1GRM4GRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6277880-B1 ANTIBODY DIRECTED ENZYME PRODUG THERAPY ZENECA LIMITED (GB) 2001-08-21 — — US disclosed
US-5958971-A PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION ZENECA LIMITED (GB) 1999-09-28 — — US disclosed
EP-0651740-B1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LTD (GB) 1998-10-21 — — EP disclosed
US-5714148-A PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS ZENECA LIMITED (GB) 1998-02-03 — — US disclosed
US-5660829-A DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE ZENECA LIMITED (GB) 1997-08-26 — — US disclosed
US-5587161-A TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME ZENECA LIMITED (GB) 1996-12-24 — — US disclosed
EP-0651740-A1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LIMITED (GB) 1995-05-10 — — EP disclosed
US-5405990-A For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents ZENECA LIMITED (GB) 1995-04-11 — — US disclosed
WO-1994002450-A1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LIMITED (GB) 1994-02-03 — — WO disclosed